$76.63
1.05%
Nasdaq, Sep 26, 10:00 pm CET
ISIN
US61023L1089
Symbol
MNPR

Monopar Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Monopar Therapeutics Inc Classifications & Recommendation:

Buy
85%
Hold
15%

Monopar Therapeutics Inc Price Target

Target Price $76.50
Price $76.63
Deviation
Number of Estimates 10
10 Analysts have issued a price target Monopar Therapeutics Inc 2026 . The average Monopar Therapeutics Inc target price is $76.50. This is lower than the current stock price. The highest price target is , the lowest is .
A rating was issued by 13 analysts: 11 Analysts recommend Monopar Therapeutics Inc to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Monopar Therapeutics Inc stock has an average upside potential 2026 of . Most analysts recommend the Monopar Therapeutics Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share $ -4.22 -1.78
38.82% 57.82%
P/E negative

12 Analysts have issued a Monopar Therapeutics Inc forecast for earnings per share. The average Monopar Therapeutics Inc EPS is

$-1.78
Unlock
. This is
27.94% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-1.38 44.13%
Unlock
, the lowest is
$-2.28 7.69%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-4.22 38.82%
2025
$-1.78 57.82%
Unlock
2026
$-3.71 108.43%
Unlock
2027
$-3.22 13.21%
Unlock
2028
$0.37 111.49%
Unlock
2029
$1.08 191.89%
Unlock
2030
$1.75 62.04%
Unlock
2031
$2.70 54.29%
Unlock
2032
$4.07 50.74%
Unlock

P/E ratio

Current -31.02 1,287.18%
2025
-43.07 38.83%
Unlock
2026
-20.64 52.08%
Unlock
2027
-23.77 15.16%
Unlock
2028
205.83 965.92%
Unlock
2029
70.87 65.57%
Unlock
2030
43.81 38.18%
Unlock
2031
28.35 35.29%
Unlock
2032
18.81 33.65%
Unlock

Current Monopar Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Chardan Capital
Locked
Locked
Locked Sep 25 2025
BTIG
Locked
Locked
Locked Sep 25 2025
Piper Sandler
Locked
Locked
Locked Sep 25 2025
Lake Street
Locked
Locked
Locked Sep 23 2025
Chardan Capital
Locked
Locked
Locked Sep 16 2025
BTIG
Locked
Locked
Locked Sep 15 2025
BTIG
Locked
Locked
Locked Sep 09 2025
Analyst Rating Date
Locked
Chardan Capital:
Locked
Locked
Sep 25 2025
Locked
BTIG:
Locked
Locked
Sep 25 2025
Locked
Piper Sandler:
Locked
Locked
Sep 25 2025
Locked
Lake Street:
Locked
Locked
Sep 23 2025
Locked
Chardan Capital:
Locked
Locked
Sep 16 2025
Locked
BTIG:
Locked
Locked
Sep 15 2025
Locked
BTIG:
Locked
Locked
Sep 09 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today